The UroNav fusion biopsy system is an innovative technology that uses a combination of MRI and ultrasound images for multi-parametric localization and targeted biopsy of the prostate. Unlike the traditional ultrasound-only based approach that takes multiple “blind” samples (and only yields successful detection rates in the 30th percentile), UroNav allows urologists to specifically target the Regions of Interest (ROI) identified with a previously performed MRI scan. The device functions similar to a GPS system in finding suspected cancerous areas within the prostate gland guiding the physician to the ROIs for a precise biopsy. The result is prostate cancer detection rates approaching 80 to 90 percent. In many cases, this technique may negate the need for multiple biopsies endured over a prolonged period of time. Patients can now benefit from a more accurate and reliable biopsy when prostate cancer is present and more confidence in a negative biopsy result when it is not.